APA (7th ed.) Citation

SJ, W., CF, H., TS, C., CC, L., CH, H., CW, H., . . . ML, Y. (2025). Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan. The Kaohsiung journal of medical sciences, 41(2), e12929. https://doi.org/10.1002/kjm2.12929

Chicago Style (17th ed.) Citation

SJ, Wang, et al. "Real-world Efficacy and Safety of Universal 8-week Glecaprevir/pibrentasvir in Patients with Chronic Hepatitis C with Early Chronic Kidney Disease or Pre-end-stage Renal Disease: Insights from a Nationwide Hepatisis C Virus Registry in Taiwan." The Kaohsiung Journal of Medical Sciences 41, no. 2 (2025): e12929. https://doi.org/10.1002/kjm2.12929.

MLA (9th ed.) Citation

SJ, Wang, et al. "Real-world Efficacy and Safety of Universal 8-week Glecaprevir/pibrentasvir in Patients with Chronic Hepatitis C with Early Chronic Kidney Disease or Pre-end-stage Renal Disease: Insights from a Nationwide Hepatisis C Virus Registry in Taiwan." The Kaohsiung Journal of Medical Sciences, vol. 41, no. 2, 2025, p. e12929, https://doi.org/10.1002/kjm2.12929.